Lung Cancer Survival Rates: Statistics by Stage, Type, and Age

Key Takeaways

• 5-year relative survival for lung cancer is approximately 25% overall, but varies dramatically by stage: localized (65%), regional (37%), and distant (9%).

• Survival depends on multiple factors including cancer stage, type, biomarker profile, age and health status, and access to newer treatments—not age alone.

• Non-small cell lung cancer (NSCLC) generally carries better prognosis than small cell lung cancer (SCLC), with NSCLC survival approximately 28–30% and SCLC approximately 7% at 5 years.

• Survival statistics are improving due to advances in immunotherapy, targeted therapy, early detection through screening, and better supportive care.

• Clinical trials offer access to cutting-edge treatments that improve survival and represent the pathway through which new therapies become standard options.

• Survival statistics represent population averages and don't predict individual outcomes—discuss your personal prognosis with your oncologist who understands your specific situation.

Understanding Lung Cancer Survival Rates

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, the overall 5-year relative survival rate for lung cancer is approximately 25%. This statistic represents the percentage of people diagnosed with lung cancer who are still living five years after diagnosis, compared to the general population of the same age and sex. Understanding what this number means—and what it doesn't—is crucial for patients and families navigating a diagnosis.

When healthcare providers discuss survival rates, they're referring to 5-year relative survival, which compares survival among cancer patients to the general population's expected survival. This differs from absolute survival, which simply measures the percentage of people alive after a given time period. Relative survival provides a more accurate picture by accounting for deaths from all causes, not just cancer. It's important to recognize that survival rates are population averages derived from thousands of patients across different demographics, stages at diagnosis, treatment options, and health backgrounds. Your individual prognosis may differ significantly from these statistics.

The SEER database, maintained by the National Cancer Institute, tracks cancer incidence and survival across the United States using data from population-based cancer registries. These statistics represent real-world outcomes for patients diagnosed between specific time periods, though data typically lags by several years due to the time required for follow-up and analysis. This means current survival rates may actually underestimate outcomes for patients today, especially those benefiting from newer treatment approaches and diagnostic advances not yet fully reflected in the statistics.

What Survival Rates Don't Tell You

Survival statistics have important limitations. They cannot predict your individual outcome—two patients with identical diagnoses may have very different life expectancies based on factors like how their body responds to treatment, their overall health, and access to specific therapies. Additionally, survival rates don't capture quality of life, treatment side effects, or the many patients who live well beyond five years. A patient diagnosed at age 45 faces very different circumstances than one diagnosed at age 75, yet both may be included in the same statistical category. Understanding these nuances helps you interpret statistics appropriately and have more meaningful conversations with your healthcare team.

Lung Cancer Survival Rates by Stage

Stage at diagnosis is one of the most important factors affecting survival. The earlier lung cancer is detected, the greater the likelihood of successful treatment and longer survival. According to SEER data, survival rates vary dramatically across the three main stage categories used for epidemiological reporting.

Localized Lung Cancer

When lung cancer is confined to the lungs without spread to lymph nodes or distant organs (localized disease), the 5-year relative survival rate is approximately 65%. This significant survival advantage reflects the ability to surgically remove tumors and treat the disease with the most aggressive curative approaches. Patients with localized disease who are candidates for surgery often have the best outcomes, particularly those with Stage I disease. The relatively high survival rate underscores why screening initiatives targeting high-risk individuals show such promise because detecting disease at this stage fundamentally changes treatment possibilities and prognosis.

Regional Lung Cancer

When cancer has spread to nearby lymph nodes or structures but remains in the chest region (regional disease), the 5-year relative survival rate drops to approximately 37%. This stage includes tumors that cannot be completely removed surgically but are still considered potentially curable with multimodal therapy combining surgery, chemotherapy, and/or radiation. Despite lower survival rates compared to localized disease, many patients with regional lung cancer achieve long-term remission or cure. Treatment at specialized cancer centers with experienced thoracic surgery and oncology teams becomes increasingly important at this stage.

Distant Lung Cancer

When cancer has metastasized to distant organs like the brain, liver, or bones (distant disease), the 5-year relative survival rate is approximately 9%. This category represents advanced disease that is generally treated with a goal of extending survival and maintaining quality of life. However, this statistic reflects historical data, and recent advances in immunotherapy and targeted therapy have meaningfully improved outcomes for many patients with distant disease. Newer treatment options that weren't available to earlier cohorts in the SEER database continue to improve survival for patients diagnosed today.

Important Context on Stage Statistics

All stages combined, the 5-year relative survival rate is approximately 25%, reflecting the fact that most lung cancers are diagnosed at regional or distant stages when symptoms finally appear. However, there's encouraging news: survival rates have been trending upward over the past two decades. Improvements in early detection through low-dose CT screening, advances in surgical techniques, and the advent of targeted and immunotherapy approaches are contributing to better outcomes. Your prognosis depends on where your cancer falls within these stage categories and multiple other factors beyond stage alone.

Survival Rates by Lung Cancer Type

Lung cancer is not one disease but several distinct types with different biology, prognosis, and treatment responses. The two major categories—non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)—show notably different survival patterns.

Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for approximately 80–85% of all lung cancer diagnoses and generally carries a better prognosis than SCLC. The 5-year relative survival rate for NSCLC is approximately 28–30% across all stages combined. This category includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma subtypes. Within NSCLC, the development of targeted therapy options for specific biomarkers, such as EGFR mutations, ALK rearrangements, and ROS1 mutations, has dramatically improved survival for patients whose tumors carry these alterations. Patients with immunotherapy-responsive tumors (those with high PD-L1 expression) have also experienced significant survival improvements.

The relatively better prognosis for NSCLC reflects both its somewhat slower growth pattern compared to SCLC and the expanded treatment arsenal now available. Adenocarcinoma, the most common type of NSCLC, occurs more frequently in non-smokers and younger patients and is often associated with specific gene mutations that can be targeted therapeutically.

Small Cell Lung Cancer (SCLC)

SCLC accounts for 10–15% of lung cancer diagnoses but is more aggressive than NSCLC. The 5-year relative survival rate for SCLC is approximately 7% across all stages combined. This low statistic reflects SCLC's rapid growth and early tendency to spread beyond the lungs. However, SCLC is highly responsive to initial chemotherapy and radiation, and patients often experience dramatic initial tumor shrinkage. The challenge is that the response is frequently temporary, with cancer often recurring within months.

The improved survival statistics for SCLC have lagged behind NSCLC partly because fewer targeted therapy options are available, though checkpoint immunotherapy agents have recently shown promise in extending survival for some SCLC patients. Limited stage SCLC (cancer confined to one lung and regional lymph nodes) carries significantly better prognosis than extensive stage disease, with some patients achieving long-term survival or cure when treated aggressively.

For detailed information about these cancer types and how they're classified, visit our guide on lung cancer types.

How Age Affects Lung Cancer Survival

Age at diagnosis influences both treatment options and survival outcomes, though the relationship is complex. It's not age itself that determines prognosis, but rather the health status, organ function, and ability to tolerate treatment that often correlate with age.

Younger Patients

Patients diagnosed with lung cancer before age 50 typically have better 5-year survival rates—approximately 35–40% across all stages—compared to older cohorts. Younger patients may have fewer comorbidities (other health conditions), better organ function to tolerate aggressive treatments, and longer life expectancy that improves five-year survival statistics. Additionally, younger patients often have adenocarcinoma or are never-smokers with EGFR mutations, both of which tend to be more responsive to targeted treatments.

However, younger patients with lung cancer may face unique challenges. Lung cancer in non-smokers and younger individuals often presents at advanced stages, and some younger patients may experience particular emotional and social impacts of diagnosis. Access to cutting-edge treatments and participation in clinical trials is often beneficial for younger patients seeking to maximize long-term survival.

Older Patients

Patients diagnosed at age 75 or older represent a growing proportion of new lung cancer diagnoses. While raw survival statistics for this group appear lower—approximately 15–18% five-year relative survival—this reflects several factors. Older patients may have limited life expectancy from competing causes (heart disease, stroke, etc.), making five-year survival less likely even with successful cancer treatment. Additionally, some older patients may decline aggressive surgery or chemotherapy in favor of radiation or supportive care focused on quality of life.

Importantly, chronological age alone should not limit treatment. Many older adults with good overall health and organ function tolerate standard cancer treatments well and achieve excellent outcomes. Older patients with early-stage disease who are healthy enough for surgery often experience survival similar to younger patients. The key is assessing individual health status and preferences rather than age as a number.

Age and Treatment Decision-Making

Age becomes most relevant in discussions about which treatments are appropriate and tolerable for an individual. Geriatric assessment—a comprehensive evaluation of an older patient's overall health, organ function, and ability to tolerate treatments—has become standard practice for older patients with cancer. Your oncologist can help determine which treatments align with your health status and goals, regardless of your age.

Factors That Influence Individual Prognosis

While population-level statistics provide important context, your individual prognosis depends on multiple factors specific to your situation. Understanding these elements helps you have more informed discussions with your healthcare team.

Stage at Diagnosis

As discussed above, stage is among the most powerful predictors of survival. Localized disease offers substantially better survival prospects than distant disease. This underscores the critical importance of screening for high-risk individuals because early detection when disease is most treatable fundamentally changes outcomes.

Cancer Type and Subtype

Whether you have NSCLC or SCLC and which subtype (adenocarcinoma, squamous cell, etc.) significantly influences prognosis and treatment options. NSCLC generally carries better prognosis than SCLC, and specific subtypes may be more responsive to particular therapies.

Biomarker Profile

For patients with NSCLC, the presence or absence of specific mutations and protein markers dramatically affects prognosis and treatment options. Patients whose tumors contain biomarkers such as EGFR mutations or ALK rearrangements often achieve significantly longer survival with targeted therapy than those with "wild-type" tumors lacking these alterations. Tumor PD-L1 expression predicts response to immunotherapy. Your oncologist should order comprehensive biomarker testing to guide personalized treatment selection.

Overall Health and Performance Status

Your overall health status including comorbidities, organ function, and ability to tolerate treatment influences both how aggressively your cancer can be treated and your ability to survive that treatment. A measure called Eastern Cooperative Oncology Group (ECOG) performance status helps oncologists assess whether patients can tolerate intensive therapies. Better performance status generally correlates with better outcomes.

Response to Treatment

How your tumor responds to initial treatment is highly predictive of long-term survival. Patients whose tumors shrink significantly with chemotherapy, surgery achieves complete resection, or immunotherapy produces durable responses generally have better survival than those with minimal response. This is why initial treatment and regular monitoring are so important—they provide information about your tumor's behavior and responsiveness.

Access to Newer Therapies

Patients with access to the newest treatment options—whether immunotherapy, targeted therapy, or clinical trial drugs—often achieve better survival than those limited to conventional approaches. Geographic location, insurance coverage, and healthcare access can unfortunately influence treatment availability. Discussing newer options and potential clinical trial participation with your team can open additional possibilities.

How Survival Rates Are Improving

The statistics in this article reflect historical data, but the trajectory of lung cancer treatment is decidedly upward. Multiple breakthroughs are steadily improving survival outcomes for newly diagnosed patients.

Immunotherapy Revolution

The advent of checkpoint inhibitors and other immunotherapy agents has fundamentally changed lung cancer treatment, particularly for advanced disease. These drugs harness the immune system to recognize and destroy cancer cells. For patients with high PD-L1 expression or microsatellite instability, immunotherapy produces responses and survival improvements that substantially exceed what traditional chemotherapy alone achieved. Combination approaches pairing immunotherapy with chemotherapy or other immunotherapy agents continue to improve outcomes.

Targeted Therapy Advances

For patients whose tumors carry actionable biomarkers, targeted therapy agents produce response rates of 70–80% compared to 30–40% with chemotherapy, with corresponding survival improvements — a finding supported by a landmark 2018 clinical trial published in the New England Journal of Medicine. New mutations are continuously being identified, and new targeted agents developed. Patients with EGFR mutations, ALK or ROS1 rearrangements, BRAF mutations, and other alterations now have multiple treatment options offering years of progression-free survival. Next-generation sequencing and liquid biopsies make comprehensive biomarker testing increasingly accessible.

Earlier Detection Through Screening

According to the National Lung Screening Trial, published in the New England Journal of Medicine, low-dose CT screening for high-risk individuals reduces lung cancer mortality by approximately 20%. When cancers are detected at earlier stages through screening, they're more likely to be surgically resectable and curable. Expanding screening programs and improving screening awareness remain critical strategies for improving overall lung cancer survival.

Improved Surgical Techniques and Supportive Care

Advances in minimally invasive surgery, perioperative management, and supportive care have made surgery safer even for older and sicker patients. Better management of treatment side effects, improved antimicrobial agents, and enhanced supportive care have reduced treatment-related mortality and enabled more patients to complete planned therapy.

Combination and Sequential Therapy Approaches

Modern treatment increasingly combines multiple modalities—surgery with chemotherapy and radiation, chemotherapy followed by immunotherapy, or immunotherapy combinations. Sequencing treatments strategically to manage side effects while maximizing benefit continues to improve outcomes.

For more information about current treatment approaches, visit lung cancer treatment options. Learn about lung cancer detection through screening guidelines and understanding cancer stages.

Clinical Trials and Survival Outcomes

Many of the improvements in lung cancer survival discussed above originated in clinical trials. Clinical trial participants contribute to advancing medical knowledge while often receiving cutting-edge therapies that may offer benefits beyond standard treatment.

How Trials Drive Improvements

Every new therapy that improves survival statistics started in a clinical trial. Immunotherapy agents, targeted therapies, and combination approaches all went through phases of testing in human subjects before becoming standard options. Patients who participated in early trials of these agents experienced improved outcomes while helping establish that these treatments work better than older approaches.

Trial Access and Benefits

Clinical trials often provide access to new treatments before they're widely available, potentially at no cost to participants. Trials offer close monitoring and care coordination, often at major cancer centers with experienced teams. Importantly, all trial participants receive standard care as a baseline, with the trial investigating whether added or alternative approaches provide additional benefit.

Individual Outcomes in Trials

Clinical trial participants often report better access to newer therapies, more frequent monitoring, and coordination of care. While trial participation doesn't guarantee better outcomes, many participants benefit from treatments that subsequently become standard options for all patients. By contributing to trials, you may directly improve your own treatment while helping future patients with lung cancer.

If you're interested in exploring treatment options that may include clinical trials, visit our resource on lung cancer clinical trials or use North's trial finder to search for studies matching your specific diagnosis and circumstances.

Frequently Asked Questions

What does 5-year survival rate mean, and does it mean I'll definitely survive 5 years?

The 5-year relative survival rate represents the percentage of people with a given cancer who are alive 5 years after diagnosis, compared to the general population of similar age. For lung cancer at 25% overall, this means that in a group of 100 people diagnosed with lung cancer, approximately 25 would be expected to survive 5 years. However, this is a population average—individual outcomes vary widely based on stage, type, biomarkers, health status, and treatment response. Some people survive much longer than 5 years, while these averages include others diagnosed at very advanced stages. Your personal prognosis depends on your specific circumstances, not the population average.

Why are survival rates for distant stage lung cancer so low?

Distant stage lung cancer has spread beyond the chest to organs like the liver, brain, or bones, making it impossible to surgically remove all disease. Historical treatment options for advanced disease were limited to chemotherapy, which typically extends survival by months rather than years. However, recent advances in immunotherapy and targeted therapy have substantially improved outcomes for some patients with distant disease, particularly those whose tumors have specific biomarkers or high immunotherapy responsiveness. The statistics cited reflect historical data and may underestimate current outcomes for newly diagnosed patients with access to newer treatments.

Does my age determine my prognosis?

Age itself is not the primary determinant of prognosis. Rather, overall health status, organ function, and ability to tolerate treatment influence both survival and which treatments are appropriate. A healthy 75-year-old with early-stage lung cancer may have outcomes similar to a 55-year-old in similar circumstances. Conversely, a younger patient with advanced disease and significant comorbidities may face a different prognosis. Your oncologist evaluates your overall health status to determine which treatments are safe and likely to benefit you, regardless of your age.

Can I beat these statistics?

Absolutely. Survival statistics represent averages across thousands of patients with vastly different circumstances. Many people diagnosed with lung cancer survive well beyond the statistical average. Factors that predict better outcomes include early-stage diagnosis, specific favorable biomarkers, good overall health, access to newer treatments, and strong response to initial therapy. Additionally, new treatments continue to improve outcomes for patients diagnosed today compared to those whose outcomes are reflected in current statistics. Working closely with your treatment team to optimize therapy and exploring newer options including clinical trials can improve your individual outcomes.

Should I participate in a clinical trial?

Clinical trials offer potential access to cutting-edge treatments that may provide benefits beyond standard therapy. All trial participants receive rigorous monitoring and care coordination. The decision to participate is personal and depends on factors like your disease stage, overall health, location, and personal preferences. Discuss potential trial options with your oncologist to understand which trials might be appropriate for your specific situation and what participation would involve. Many improvements in lung cancer survival originated in clinical trials, so trial participants often benefit from treatments that subsequently help many other patients.

Ready to explore clinical trials that may be right for you? Start your search with North's trial finder to discover studies matching your specific diagnosis and circumstances.

References

1. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. "Cancer Statistics." seer.cancer.gov.

2. National Cancer Institute. "SEER Cancer Statistics Explorer." seer.cancer.gov.

3. National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3.2026." nccn.org.

4. Soria JC, Ohe Y, Vansteenkiste J, et al. "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer." New England Journal of Medicine. 2018;378(2):113–125.

5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. "Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer." New England Journal of Medicine. 2016;375(19):1823–1833.

6. National Lung Screening Trial Research Team. "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening." New England Journal of Medicine. 2011;365(5):395–409.